Our Expanded Access Policy
Imvax is a clinical-stage biotechnology company focused on developing innovative personalized, whole tumor-derived immunotherapies for cancers.
Expanded access, sometimes called “compassionate use,” is a pathway for a patient with an immediately life-threatening condition or serious disease or condition to potentially gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Currently, Imvax is not making its investigational therapies available for expanded access. Imvax believes that investigational therapies should be studied in patients as part of clinical trials designed to obtain data on safety and efficacy that may be used to support approval of the product which would lead to subsequent wider availability for patients. Our clinical trial programs are the primary way to get access to an Imvax investigational therapy. Imvax strongly encourages patients to speak with their treating physicians and when possible, to participate in clinical trials.
In the event Imvax decides to consider expanded access in the future, it will evaluate and respond to each request that it receives on a case-by-case basis. Any such request for expanded access to Imvax investigational therapies must come from a patient’s treating physician.
Information about our investigational therapies and ongoing clinical trials can be found on https://www.clinicaltrials.gov/ct2/show/NCT04485949.
As permitted by the 21st Century Cures Act, Imvax may revise this Expanded Access Policy at any time. The posting of this policy by Imvax shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.
If you have additional questions about our investigational therapies, please speak with your treating physician or contact Imvax at email@example.com.